(Q37951907)

25 August 2017

title

Linaclotide: a novel approach to the treatment of irritable bowel syndrome (English)

1 reference

25 August 2017

1 reference

ChEBI release 2020-05-28

Terri M Wensel

1

1 reference

25 August 2017

David R Luthin

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 November 2011

1 reference

Annals of Pharmacotherapy

25 August 2017

published in

1 reference

25 August 2017

volume

45

1 reference

25 August 2017

issue

12

1 reference

25 August 2017

page(s)

1535-1543

1 reference

An evidence-based position statement on the management of irritable bowel syndrome

25 August 2017

cites work

1 reference

Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases

21 January 2018

1 reference

Taking a lesson from microbial diarrheagenesis in the management of chronic constipation.

21 January 2018

1 reference

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit

21 January 2018

1 reference

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract

21 January 2018

1 reference

Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.

21 January 2018

1 reference

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1Q428

1 reference

25 August 2017

1 reference